Kiora Pharmaceuticals, Inc. (KPRX) Stock Price & Analysis
Kiora Pharmaceuticals, Inc. (KPRX) — price $2.56 (-0.78%), as of the Oct 2, 2026 trading session; market cap $11.4M.
Educational signal · not a buy or sell recommendation · How to read this
Kiora Pharmaceuticals, Inc. · KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapies for ophthalmic diseases.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.56 | |
| Change on the day | -0.78% | |
| 52-week range | $1.76 – $2.95 | |
| Market capitalisation | $11.4M | |
| Shares traded on the day | 3.4K |
Price & events
Other perspectives
Council score for Kiora Pharmaceuticals (KPRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
0 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read date unavailable · not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the KPRX film — every key number, told as a short cinematic story
~2 min · open the film
What is Kiora Pharmaceuticals (KPRX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Kiora Pharmaceuticals, Inc. (KPRX) is the company analyzed here. It employs 13 people and is led by Brian Strem. In Q2 FY2026 it reported revenue of $0 and net income of -$2M. The market values it at $11.4M.
What do the latest results show for Kiora Pharmaceuticals (KPRX)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0. Against analyst estimates the company has EPS beat 6 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$2M | -$0.34 (diluted) |
| Q1 FY2026 | $0 | -$2M | -$0.58 (diluted) |
| Q4 FY2025 | $0 | -$7M | -$1.59 (diluted) |
| Q3 FY2025 | $0 | $26,806 | $0.01 (diluted) |
What are the financial strengths and risks for Kiora Pharmaceuticals (KPRX)?
Short answer
The distress and quality screens read Altman Z -9.11 · Piotroski F 2. Trailing ratios: ROE -56.4% · ROA -21.9% · current ratio 8.97.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -9.11 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-56.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 17, 2026
- Transactions
- 9
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 0
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Kiora Pharmaceuticals (KPRX)?
- Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
- Kiora Pharmaceuticals Announces Exclusive License Agreement With Chong Kun Dang For KIO-301 In South Korea For $1M Upfront, Plus Milestones And Royalties
- Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
- Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Kiora Pharmaceuticals Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the KPRX research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is KPRX a good stock to buy?
Stock Expert AI does not rate KPRX buy, sell or hold. Kiora Pharmaceuticals, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the KPRX stock price today?
The last price recorded on this page for Kiora Pharmaceuticals, Inc. (KPRX) is $2.56, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for KPRX?
Kiora Pharmaceuticals, Inc. faces several risks, including regulatory approval risks associated with its clinical trials, which may impact the timeline for product commercialization.
What are the key factors to evaluate for KPRX?
Evaluate KPRX on fundamentals, analyst consensus, and risk factors. Strategic Partnerships: Kiora Pharmaceuticals may explore strategic partnerships or collaborations with larger pharmaceutical companies to enhance its research capabilities and market reach. Not financial advice.
How frequently does KPRX data refresh on this page?
KPRX's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven KPRX's recent stock price performance?
Kiora Pharmaceuticals, Inc. (KPRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused expertise in ophthalmic disease therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KPRX overvalued or undervalued right now?
Kiora Pharmaceuticals, Inc. (KPRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KPRX before investing?
Before investing in Kiora Pharmaceuticals, Inc. (KPRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (15 figures)
The 15 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $2.56 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T17:14:30.482Z. | |
px.change | Change on the day | -0.78% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $11.4M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T17:14:29.543Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.02 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.4K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$2M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 9 transactions · 0 purchases, 0 sales, 9 other transactions · 9 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 17, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $1.76 – $2.95 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.employees | Employees | 13 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.ceo | Chief executive | Brian Strem | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-18 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -9.11 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -56.4% · ROA -21.9% · current ratio 8.97 | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.